170 CHAPTER 8 51. Godino C, Bodega F, Melillo F, Rubino F, Parlati AL, Cappelletti A, et al. Inappropriate dose of nonvitamin-K antagonist oral anticoagulants: prevalence and impact on clinical outcome in patients with nonvalvular atrial fibrillation. J Cardiovasc Med (Hagerstown). 2020;21(10):751–8. 52. Hecker J, Marten S, Keller L, Helmert S, Michalski F, Werth S, et al. Effectiveness and safety of rivaroxaban therapy in daily-care patients with atrial fibrillation: results from the Dresden NOAC registry. Thromb Haemost. 2016;115(5):939–49. 53. Helmert S, Marten S, Mizera H, Reitter A, Sahin K, Tittl L, et al. Effectiveness and safety of apixaban therapy in daily-care patients with atrial fibrillation: results from the Dresden NOAC registry. J Thromb Thrombolysis. 2017;44(2):169–78. 54. Hussain S, Gebran N, Hussain K, Soliman K. Drug use evaluation of dabigatran in a tertiary care hospital in United Arab Emirates. Eur J Hosp Pharm. 2012;20(2):106–9. 55. Inoue H, Umeyama M, Yamada T, Hashimoto H, Komoto A, Yasaka M. Safety and effectiveness of apixaban in Japanese patients with nonvalvular atrial fibrillation in clinical practice: a regulatory postmarketing surveillance, the STANDARD study. J Arrhythm. 2019;35(3):506–14. 56. Isaacs AN, Doolin M, Morse C, Shiltz E, Nisly SA. Medication utilization evaluation of dabigatran and rivaroxaban within a large, multi-center health system. Journal of HealthSystem Pharmacy Residents. 2013;2(3). 57. Isaacs AN, Doolin M, Morse C, Shiltz E, Nisly SA. Medication utilization evaluation of dabigatran and rivaroxaban within a large, multi-center health system. Am J Health Syst Pharm. 2016;73(suppl 1):S35-41. 58. Jang BM, Lee OS, Shin EJ, Cho EJ, Suh SY, Cho YS, et al. Factors related to inappropriate edoxaban use. J Clin Pharm Ther. 2019;44(5):760–7. 59. Jansson M, Själander S, Sjögren V, Renlund H, Norrving B, Själander A. Direct comparisons of effectiveness and safety of treatment with apixaban, dabigatran and rivaroxaban in atrial fibrillation. Thromb Res. 2020;185:135–41. 60. Kohsaka S, Katada J, Saito K, Jenkins A, Li B, Mardekian J, et al. Safety and effectiveness of non-vitamin K oral anticoagulants versus warfarin in real-world patients with non-valvular atrial fibrillation: a retrospective analysis of contemporary Japanese administrative claims data. Open Heart. 2020;7(1):e001232. 61. Kotalczyk A, Guo Y, Wang Y, Lip GYH. Are low doses of non-vitamin K antagonists effective in Chinese patients with atrial fibrillation? A report from the Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry. International Journal of Stroke. 2021;17474930211053140 62. Larsen TB, Rasmussen LH, Skjøth F, Due KM, Callréus T, Rosenzweig M, et al. Efficacy and safety of dabigatran etexilate and warfarin in ‘real-world’ patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol. 2013;61(22):2264–73. 63. Lee S, Sayers M, Lip G, Lane D. Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic. Int J Clin Pract. 2015;69(11):1341–8. 64. Li XS, Deitelzweig S, Keshishian A, Hamilton M, Horblyuk R, Gupta K, et al. Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in ‘realworld’ clinical practice: a propensity-matched analysis of 76,940 patients. Thromb Haemost. 2017;117(6):1072–82. 65. Marzona I, Proietti M, Colacioppo P, Foresta A, Baviera M. Effectiveness and safety of high and low dose NOACs in patients with atrial fibrillation. Eur J Intern Med. 2021;88:118–22.
RkJQdWJsaXNoZXIy MTk4NDMw